Which has preferable valuation & earnings, GSK or RPRX?

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.33 $7.54B $3.20 15.48 Royalty Pharma $2.38B 14.19 $770.95M $1.45 40.41

Is GSK or RPRX more profitable?

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.56% 43.23% 11.60% Royalty Pharma 32.14% 30.01% 14.91%

Does the media prefer GSK or RPRX?

In the previous week, Royalty Pharma had 7 more articles in the media than GSK. MarketBeat recorded 10 mentions for Royalty Pharma and 3 mentions for GSK. Royalty Pharma's average media sentiment score of 0.90 beat GSK's score of 0.45 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SNY or RPRX?

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanofi $49.35B 2.15 $8.84B $1.91 22.89 Royalty Pharma $2.38B 14.19 $770.95M $1.45 40.41

Is SNY or RPRX more profitable?

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Sanofi 8.66% 14.19% 7.95% Royalty Pharma 32.14% 30.01% 14.91%

Does the media prefer SNY or RPRX?

In the previous week, Royalty Pharma had 4 more articles in the media than Sanofi. MarketBeat recorded 10 mentions for Royalty Pharma and 6 mentions for Sanofi. Royalty Pharma's average media sentiment score of 0.90 beat Sanofi's score of 0.48 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TAK or RPRX?

Royalty Pharma has a consensus price target of $60.86, indicating a potential upside of 3.85%. Given Royalty Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media refer more to TAK or RPRX?

In the previous week, Takeda Pharmaceutical had 14 more articles in the media than Royalty Pharma. MarketBeat recorded 24 mentions for Takeda Pharmaceutical and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.90 beat Takeda Pharmaceutical's score of 0.15 indicating that Royalty Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 13 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RPRX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Royalty Pharma. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.90 beat Teva Pharmaceutical Industries' score of 0.90 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 6 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RPRX or ONC?

In the previous week, BeOne Medicines had 20 more articles in the media than Royalty Pharma. MarketBeat recorded 30 mentions for BeOne Medicines and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.90 beat BeOne Medicines' score of 0.44 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 11 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Royalty Pharma (RPRX) Competitors

$58.60 +0.04 (+0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$58.59 -0.01 (-0.02%)

As of 07:55 PM Eastern

Compare

RPRX vs. GSK, SNY, TAK, TEVA, and ONC

Should you buy Royalty Pharma stock or one of its competitors? Royalty Pharma's main competitors and comparable companies include GSK (GSK), Sanofi (SNY), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), and BeOne Medicines (ONC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Royalty Pharma compare to GSK?

GSK (NYSE:GSK) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

15.7% of GSK shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GSK has higher revenue and earnings than Royalty Pharma. GSK is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.33	$7.54B	$3.20	15.48
Royalty Pharma	$2.38B	14.19	$770.95M	$1.45	40.41

In the previous week, Royalty Pharma had 7 more articles in the media than GSK. MarketBeat recorded 10 mentions for Royalty Pharma and 3 mentions for GSK. Royalty Pharma's average media sentiment score of 0.90 beat GSK's score of 0.45 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has a net margin of 32.14% compared to GSK's net margin of 14.56%. GSK's return on equity of 43.23% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.56%	43.23%	11.60%
Royalty Pharma	32.14%	30.01%	14.91%

GSK presently has a consensus target price of $53.00, indicating a potential upside of 6.98%. Royalty Pharma has a consensus target price of $60.86, indicating a potential upside of 3.85%. Given GSK's higher possible upside, research analysts clearly believe GSK is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.10
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.6%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. GSK pays out 55.9% of its earnings in the form of a dividend. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

Summary

Royalty Pharma beats GSK on 12 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to Sanofi?

Sanofi (NASDAQ:SNY) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Sanofi pays out 92.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 5 consecutive years.

In the previous week, Royalty Pharma had 4 more articles in the media than Sanofi. MarketBeat recorded 10 mentions for Royalty Pharma and 6 mentions for Sanofi. Royalty Pharma's average media sentiment score of 0.90 beat Sanofi's score of 0.48 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

14.0% of Sanofi shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sanofi presently has a consensus price target of $49.50, suggesting a potential upside of 13.22%. Royalty Pharma has a consensus price target of $60.86, suggesting a potential upside of 3.85%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	1 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.40
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 32.14% compared to Sanofi's net margin of 8.66%. Royalty Pharma's return on equity of 30.01% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	8.66%	14.19%	7.95%
Royalty Pharma	32.14%	30.01%	14.91%

Sanofi has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Sanofi has higher revenue and earnings than Royalty Pharma. Sanofi is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$49.35B	2.15	$8.84B	$1.91	22.89
Royalty Pharma	$2.38B	14.19	$770.95M	$1.45	40.41

Summary

Royalty Pharma beats Sanofi on 14 of the 20 factors compared between the two stocks.

How does Royalty Pharma compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Royalty Pharma (NASDAQ:RPRX) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 2.7%. Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Takeda Pharmaceutical pays out 141.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Royalty Pharma has raised its dividend for 5 consecutive years.

In the previous week, Takeda Pharmaceutical had 14 more articles in the media than Royalty Pharma. MarketBeat recorded 24 mentions for Takeda Pharmaceutical and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.90 beat Takeda Pharmaceutical's score of 0.15 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	13 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 18.8% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Royalty Pharma has a consensus price target of $60.86, indicating a potential upside of 3.85%. Given Royalty Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Royalty Pharma has a net margin of 32.14% compared to Takeda Pharmaceutical's net margin of 3.80%. Royalty Pharma's return on equity of 30.01% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	3.80%	10.95%	5.34%
Royalty Pharma	32.14%	30.01%	14.91%

Takeda Pharmaceutical has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Royalty Pharma has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

Royalty Pharma has lower revenue, but higher earnings than Takeda Pharmaceutical. Royalty Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	2.00	-$1.01B	$0.34	51.89
Royalty Pharma	$2.38B	14.19	$770.95M	$1.45	40.41

Summary

Royalty Pharma beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Royalty Pharma (NASDAQ:RPRX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Royalty Pharma has a net margin of 32.14% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

Teva Pharmaceutical Industries has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	14.19	$770.95M	$1.45	40.41
Teva Pharmaceutical Industries	$17.26B	2.48	$1.41B	$0.60	61.31

Royalty Pharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Royalty Pharma currently has a consensus price target of $60.86, indicating a potential upside of 3.85%. Teva Pharmaceutical Industries has a consensus price target of $42.22, indicating a potential upside of 14.78%. Given Teva Pharmaceutical Industries' higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Royalty Pharma. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.90 beat Teva Pharmaceutical Industries' score of 0.90 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	6 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Royalty Pharma and Teva Pharmaceutical Industries tied by winning 8 of the 16 factors compared between the two stocks.

How does Royalty Pharma compare to BeOne Medicines?

Royalty Pharma (NASDAQ:RPRX) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Royalty Pharma presently has a consensus price target of $60.86, suggesting a potential upside of 3.85%. BeOne Medicines has a consensus price target of $402.14, suggesting a potential upside of 15.73%. Given BeOne Medicines' higher probable upside, analysts plainly believe BeOne Medicines is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Royalty Pharma has higher earnings, but lower revenue than BeOne Medicines. Royalty Pharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	14.19	$770.95M	$1.45	40.41
BeOne Medicines	$5.34B	7.14	$286.93M	$5.68	61.18

In the previous week, BeOne Medicines had 20 more articles in the media than Royalty Pharma. MarketBeat recorded 30 mentions for BeOne Medicines and 10 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.90 beat BeOne Medicines' score of 0.44 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	11 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Royalty Pharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Royalty Pharma has a net margin of 32.14% compared to BeOne Medicines' net margin of 10.70%. Royalty Pharma's return on equity of 30.01% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
BeOne Medicines	10.70%	14.23%	7.82%

Summary

Royalty Pharma and BeOne Medicines tied by winning 8 of the 16 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPRX vs. The Competition

Export

Metric	Royalty Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33.72B	$11.89B	$7.06B	$13.10B
Dividend Yield	1.61%	2.70%	2.57%	10.45%
P/E Ratio	40.41	775.15	269.06	25.28
Price / Sales	14.19	741.16	592.96	87.71
Price / Cash	12.26	66.45	70.48	50.90
Price / Book	3.45	11.60	12.91	6.24
Net Income	$770.95M	$2.77B	$3.45B	$347.60M
7 Day Performance	3.22%	0.17%	1.12%	1.07%
1 Month Performance	5.26%	0.35%	1.79%	1.03%
1 Year Performance	60.55%	161.52%	67.69%	20.77%

Royalty Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPRX Royalty Pharma	4.3671 of 5 stars	$58.60 +0.1%	$60.86 +3.9%	+60.6%	$33.72B	$2.38B	40.41	80	Analyst Forecast
GSK GSK	3.5355 of 5 stars	$52.03 -1.8%	$53.00 +1.9%	+28.7%	$107.12B	$43.07B	16.27	66,841	Dividend Cut Gap Down
SNY Sanofi	2.8745 of 5 stars	$43.48 +0.0%	$49.50 +13.8%	-10.2%	$105.37B	$49.35B	22.76	74,846
TAK Takeda Pharmaceutical	3.2769 of 5 stars	$17.55 +0.6%	N/A	+17.9%	$55.91B	$28.32B	51.62	47,000	Insider Trade
TEVA Teva Pharmaceutical Industries	4.0616 of 5 stars	$36.04 +1.9%	$42.00 +16.5%	+112.2%	$41.20B	$17.26B	60.07	33,950	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPRX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Royalty Pharma (RPRX) Competitors

RPRX vs. GSK, SNY, TAK, TEVA, and ONC

How does Royalty Pharma compare to GSK?

Summary

How does Royalty Pharma compare to Sanofi?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Summary

How does Royalty Pharma compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Royalty Pharma (RPRX) Competitors

RPRX vs. GSK, SNY, TAK, TEVA, and ONC

How does Royalty Pharma compare to GSK?

Do insiders and institutionals hold more shares of GSK or RPRX?

Which has preferable valuation & earnings, GSK or RPRX?

Does the media prefer GSK or RPRX?

Is GSK or RPRX more profitable?

Do analysts prefer GSK or RPRX?

Is GSK or RPRX a better dividend stock?

Which has more risk and volatility, GSK or RPRX?

Summary

How does Royalty Pharma compare to Sanofi?

Is SNY or RPRX a better dividend stock?

Does the media prefer SNY or RPRX?

Do institutionals & insiders believe in SNY or RPRX?

Do analysts recommend SNY or RPRX?

Is SNY or RPRX more profitable?

Which has more risk & volatility, SNY or RPRX?

Which has better valuation and earnings, SNY or RPRX?

Summary

How does Royalty Pharma compare to Takeda Pharmaceutical?

Is TAK or RPRX a better dividend stock?

Does the media refer more to TAK or RPRX?

Do insiders and institutionals hold more shares of TAK or RPRX?

Do analysts rate TAK or RPRX?

Is TAK or RPRX more profitable?

Which has more volatility & risk, TAK or RPRX?

Which has better valuation and earnings, TAK or RPRX?

Summary

How does Royalty Pharma compare to Teva Pharmaceutical Industries?

Is RPRX or TEVA more profitable?

Which has stronger valuation and earnings, RPRX or TEVA?

Which has more volatility & risk, RPRX or TEVA?

Do analysts prefer RPRX or TEVA?

Do insiders and institutionals believe in RPRX or TEVA?

Does the media favor RPRX or TEVA?

Summary

How does Royalty Pharma compare to BeOne Medicines?

Do analysts prefer RPRX or ONC?

Do insiders & institutionals have more ownership in RPRX or ONC?

Which has higher earnings and valuation, RPRX or ONC?

Does the media favor RPRX or ONC?

Which has more volatility and risk, RPRX or ONC?

Is RPRX or ONC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPRX vs. The Competition

Royalty Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools